A research study focusing on magic mushrooms in Canada revealed that nearly 80% of participants support the idea of psilocybin being available as a medical treatment for patients undergoing distress. Additionally, about two-thirds of the Canadian participants in the same study agreed on the legal accessibility of psilocybin for those in need.
Beyond increasing the availability of the substance, a noteworthy 84.8 percent of participants advocate for the public health system to cover the costs of such therapies. Psilocybin is considered a viable treatment option by a majority of Canadians, especially for managing end-of-life distress.
[toc]
Key Insights:
- Inhabitants of Québec, Ontario, Alberta, and British Columbia acknowledge psilocybin as a valid medical alternative for managing end-of-life existential distress.
- Magic mushrooms are regarded as safe for treating existential distress.
- Participants in two double-blind trials observed immediate and long-lasting benefits, with effects persisting six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their mortality. Patients may endure feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This type of distress significantly impacts patients with life-threatening illnesses, potentially leading to thoughts of hastening death or considering suicide.
Generally, those grappling with terminal illnesses or significant life changes are the most likely to experience this type of distress. It severely impacts their mental health and overall life quality.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. However, it may require multiple sessions and may not be effective for everyone.
The effectiveness of such therapy is often uncertain, leading many individuals to seek alternative treatments.
Health Canada’s Take on Psilocybin as a Therapeutic Option
Over the last two decades, preliminary clinical studies have highlighted the possible advantages of psychedelic substances in managing complex mental conditions. Specifically, Psilocybin has demonstrated a quick and lasting reduction of existential distress in patients approaching the end of their lives.
In recognition of these potential benefits of hallucinogenic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare providers to request controlled substances for their patients.
Canadian Support for Psilocybin Access
A study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Surveyed 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, with 19% having previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% feel psilocybin should be included in medical treatment. 84.8% endorse the public health system providing this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers underscored the uniqueness of their study as it focuses on using psychoactive substances for managing existential distress in end-of-life situations.
Reasons for Canadian Support of Psilocybin Use
An increasing number of Canadians are supporting the use of psilocybin as treatment, mainly due to the discoveries made by reputable research institutions. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. No severe adverse health effects, such as multi-organ failure, have been reported by subjects across various studies.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The benefits of the therapy, which can last up to six months or more, are largely connected to mystical experiences that elicit a profound sense of unity and deep emotional insights. |
| New York University Study | A group of 29 patients was randomly chosen to receive either psilocybin or the active placebo, niacin. | The results were consistent with those of the Johns Hopkins study. Patients who received psilocybin reported psychological relief along with an improved outlook on life and death. |
| BMC Palliative Care | A total of nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The aim of the study was to explore the perceptions of palliative care professionals regarding existential distress and their views on psychedelic therapy as a potential treatment. | Palliative care professionals reported that psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
Apart from scientific studies, there are numerous patient accounts that reinforce the effectiveness of psilocybin in promoting mental wellbeing and enhancing the quality of life.
Yokoi’s Journey
Mio Yokoi, who was diagnosed with terminal stage 4 pancreatic cancer, shared a transformative experience during her assisted therapy. She envisioned herself on a raft, surrounded by nature, and in the company of whimsical creatures. This imagery evoked in her a profound realization of her connection with the universe, bringing her immense peace and affirmation.
Despite receiving conventional mental health support, Yokoi continued to struggle with severe anxiety and distress after her diagnosis. Psilocybin therapy allowed her to reconnect with her body and experience a tangible sense of love and support, significantly improving her emotional and mental health.
Chrissy’s Story
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer, which had metastasized to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant decreases in her anxiety, depression, fear of dying, hopelessness, and feelings of demoralization. In response to questions about any changes in her religious or spiritual beliefs following her therapy session, she shared that the experiences had brought a sense of reality and purpose to her beliefs.
Brenda’s Experience
Brenda, a woman in her sixties, was diagnosed with stage I colon cancer. The screening process revealed that she had never used hallucinogens and fulfilled the criteria for Chronic Adjustment Disorder with accompanying Anxiety.
Throughout her therapy, Brenda underwent the experience of dying twice, which led to a newfound understanding and acceptance of death as an integral and beautiful part of life. She attributed her healing journey from childhood trauma to this study. Her data reflected this significant transformation. A decrease in anxiety and fear of death, along with an increase in spirituality, were observed.
Magic Mushroom Products Available in Canada
At present, access to psilocybin capsules and other products designed to alleviate existential distress or other mental health concerns can be limited. Nonetheless, reliable online dispensaries serve as a valuable resource for obtaining these products when needed.
| Specification | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and certain surrounding South American nations. | Discovered in Cambodia, specifically around the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became famous in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Similarly moderately potent; perfect for novices. | Exceptionally potent; suggested for those with intermediate to advanced experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced colour perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Induces an energizing and long-lasting high, minor visual changes, increased creativity, euphoria, a smooth physical high, fractal imagery, and feelings of happiness. | Invokes profound shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products for Easing End-of-life Discomfort
Patients nearing the end of their lives often face considerable existential distress. Traditional treatments sometimes fail to provide sufficient relief, causing an increase in Canadian public support for easier access to magic mushrooms within the healthcare system. This rising public interest could We implore regulatory authorities to consider the therapeutic potential of magic mushrooms. For your psychedelic needs and shroom delivery, rely on 3 Amigos Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Psychedelic-assisted therapy (PAT) experiences can greatly differ from one patient to another. To ensure a positive outcome, it’s crucial to prepare adequately and follow specific steps. A comprehensive screening and mental readiness is necessary before patients take the substance.
- Pre-Session Preparation: Patients undergo a detailed evaluation, during which the therapist discusses the patient’s goals and expectations to set the intentions for the therapy. The therapist also provides explanations on the procedure and what should be expected during the session.
- The Session: A controlled dose of the substance is administered to patients in a comfortable, distraction-free environment that promotes relaxation and introspection. The therapist remains present throughout to offer constant support and direction.
- Post-Session Integration Therapy: This therapy helps patients make sense of their experiences. Follow-up sessions provide ongoing support and counselling to consolidate the insights and transformations gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, particularly the 5-HT2A receptor. This interaction can lead to alterations in perception, mood, and cognition, culminating in significant shifts in consciousness, emotional revelations, and new viewpoints.
Is psilocybin therapy available to everyone?
Not everyone is a suitable candidate for psilocybin therapy. Patients with specific mental health conditions or existential distress are thoroughly screened to rule out those with a history of psychosis.
Related Articles:
